DLD Asset Management’s Terns Pharmaceuticals TERN Stock Holding History

DLD Asset Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-47,025	Closed	-$2.48M	–	466
2026 Q1	$2.48M	Buy	47,025 +42,025	+841%	+$1.73M	0.23%	58
2025 Q4	$202K	Sell	5,000 -5,000	-50%	-$116K	0.01%	281
2025 Q3	$75.1K	Sell	10,000 -27,047	-73%	-$173K	0.01%	279
2025 Q2	$138K	Buy	+37,047	New	+$116K	0.01%	218

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

DLD Asset Management's TERN Position: Q2 2026 in Review

DLD Asset Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 47,025 shares — an estimated $2.48M sold.

DLD Asset Management first reported a position in TERN in Q2 2025 and held it in 4 quarters. The position peaked at $2.48M in Q1 2026. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

DLD Asset Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
DLD Asset Management sold 47,025 Terns Pharmaceuticals shares in Q2 2026, an estimated $2.48M.
DLD Asset Management first reported a position in Terns Pharmaceuticals in Q2 2025 and held it in 4 quarters.
DLD Asset Management's Terns Pharmaceuticals position peaked at $2.48M in Q1 2026.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on DLD Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.